Patients with metastatic breast cancer have a poor progThis study was designed to determine the complete nosis, with a median survival of approximately 2 years. 1
with the goal of eradicating small numbers of malignant period, on days −10 to day −1. Four patients received posttransplant radiation to areas of persistent abnormalities on cells that may have been unknowingly reinfused with the autograft.
the radiograph or bone scan (three patients) or to the chest wall (one patient). Equivalent dose and fractionation schedules to 6000 cGy in 200 cGy fractions were used.
Materials and methods

Post-transplant consolidation chemotherapy: Patients who
Patient eligibility achieved either a CR, PR, SD or who had no evidence of disease at transplant were to receive four cycles of postEligibility criteria included: (1) histologic tissue diagnosis transplant consolidation chemotherapy every 3 to 4 weeks. of breast cancer; (2) age between 16 and 60 years; (3) stage Consolidation was to begin no earlier than day 60 following IV disease (patients with stage IV disease rendered free the transplant or when the peripheral blood counts had recoof disease by surgery, radiotherapy or chemotherapy were vered to an ANC Ͼ1000/l and platelet count Ͼ50 000/l. eligible); (4) estrogen receptor (ER)-negative disease or
Patients received 5-fluorouracil (5-FU), 750 mg/m 2 /day by ER-positive disease after failing hormonal therapy; (5) no continuous intravenous infusion on days 1-3; and cisplatin, more than one prior therapy for metastatic disease; (6) East-75 mg/m 2 over 1 h on day 1. The doses of 5-FU and cisplaern Cooperative Oncology Group (ECOG) performance tin were modified based on the peripheral blood counts status of zero or one; (7) serum creatinine Ͻ1.5 mg/dl or obtained on the day of treatment as follows: if the ANC a creatinine clearance у50 cc per min; (8) a forced vital was у2000/l and platelet count у100 000/l, 100% of capacity у75% of predicted and diffusing capacity у50% the planned doses were given. If the ANC was between of predicted; (9) normal left ventricular ejection fraction; 1500 and 1999/l or the platelet count was between 75 000 (10) negative HIV antibody serology; (11) informed conand 99 999/l, 75% of the doses were given. If the ANC sent by procedures approved by the Institutional Review was between 1000 and 1499/l or the platelet count was Board of Northwestern University.
between 50 000 and 74 999/l, 50% of the doses were Patients with pelvic bone metastases identified by bone given. If the ANC was Ͻ1000/l or the platelet count was scan were excluded from conventional bone marrow har-Ͻ50 000/l, chemotherapy was delayed for 1 week or more vesting and were eligible for peripheral blood stem cell until the peripheral blood counts met criteria for at least transplantation with identical high-dose chemotherapy.
50% of the planned doses to be given. Patients with central nervous system disease at any time prior to transplantation were ineligible.
Bone marrow and peripheral blood stem cell harvest: Bone marrow was obtained by multiple aspirations Study design and treatment plan from the posterior iliac crests under general anesthesia. A Pre-transplant induction chemotherapy: Patients with minimum of 2 × 10 8 nucleated marrow cells/kg body recurrent disease less than 1 year after the completion of weight was collected. After filtration to remove particulate chemotherapy or those who progressed on adriamycinmatter, a buffy coat was prepared using the COBE 2991 based chemotherapy for metastatic disease proceeded cell processor (COBE, Denver, CO, USA). Cryopreservdirectly to high-dose chemotherapy with transplantation.
ation was performed by controlled-rate freezing in DMSO, Patients who received adjuvant treatment and failed more at a final concentration of 4 × 10 7 cells/ml. Patients with than 1 year after the completion of chemotherapy received bone marrow metastases identified on bone marrow core pre-transplant induction chemotherapy. Seventeen patients biopsy or with pelvic bone metastases as determined by received two to four cycles of continuous infusion adriamybone scan were transplanted using steady-state or growth cin and vinblastine, administered sequentially every 21 factor-primed peripheral blood-derived hematopoietic prodays (adriamycin, 25 mg/m 2 /day, days 1 and 2; vinblastine, genitor cells (PBPC). Peripheral blood mononuclear cells 1.5 mg/m 2 /day, days 3 to 6). Four cycles of therapy were were harvested using a cell separator (Fenwall CS-3000 recommended to provide maximal cytoreduction.
Plus, Baxter Healthcare, Deerfield, IL, USA; or Cobe Spectra, Cobe, Lakewood, CO, USA) by five to nine 3-h (10 l) High-dose chemotherapy: The high-dose chemotherapy continuous flow leukaphereses. The mean total number of regimen included cyclophosphamide, 35 mg/kg daily, given mononuclear cells collected per patient was 8 × 10 8 on days −6, −4 and −2 by intravenous infusion; and thicells/kg. The mononuclear cells were resuspended with otepa, 6.0 mg/kg/day on days −6, −4 and −2, given before autologous plasma to a concentration of approximately the cyclophosphamide. After 39 patients had been treated р2 × 10 8 nucleated cells/ml and then diluted with an equal at these doses without significant extramedullary toxicity, volume of freezing solution containing 20% autologous the dose of cyclophosphamide was increased to 2.5 g daily plasma, 20% DMSO and 60% TC-199. Cryopreservation on days −6, −4 and −2.
was accomplished by controlled-rate freezing to −100°C. The cells were stored in the liquid phase of nitrogen (−196°C). Thirty patients received bone marrow as the only Radiation therapy: In five patients, lesions that measured Ͼ3 cm at the time of transplant were irradiated pre-transsource of hematopoietic stem cells, 15 patients received only peripheral blood-derived stem cells and three patients plant with a 1 to 2 cm margin. The dose and schedule of radiation was 180 Gy, administered twice daily with a 5-received both (two because an inadequate number of peripheral blood-derived stem cells was obtained and one 6-h interval for a total dose of 2880 cGy over a 10-day because of intolerance to growth factor given for peripheral from the day of bone marrow or stem cell transplantation to the day of death from any cause. Event-free survival blood stem cell mobilization).
(EFS) was measured from the day of transplant to the day of death from any cause or to the day of objectively docuSupportive care: All patients were given prophylactic trimethoprim-sulfamethoxazole and either nystatin, fluconamented progression. Overall survival (OS) and EFS were analyzed using Kaplan-Meier product limit curves, 24 which zole or clotrimazole troches. Packed red blood cells were transfused to maintain the hemoglobin у8.0 gm/dl, and were compared using the log-rank test. 25 Confidence intervals for EFS and OS were calculated using the binomial either single-donor or pooled random-donor platelets were transfused to maintain a platelet count у20 000/l in the model. 26 Data were analyzed as of 1 April 1997. absence of bleeding. Empiric broad-spectrum antibiotics (usually an aminoglycoside and a semisynthetic antipseudomonal penicillin) were administered to neutropenic (Ͻ500 Results neutrophils/l) patients with fever у38°C. Amphotericin B was given empirically if fever Ͼ38°C persisted in neutropAccrual enic patients for 3 or more days despite broad-spectrum Between February 1989 and November 1993, 48 patients antibiotics. When hematopoietic growth factors (HGFs) with advanced breast cancer received high-dose chemobecame commercially available in March 1991, all patients therapy followed by autologous bone marrow or stem cell received either granulocyte colony-stimulating factor (Gtransplantation at Northwestern Memorial Hospital (Robert CSF), 5 g/kg, or granulocyte-macrophage colony-stimul-H Lurie Cancer Center of Northwestern University). Patient ating factor (GM-CSF), 250 g/m 2 subcutaneously daily characteristics are detailed in Table 1 . Twelve patients had post-transplant, beginning on the day of marrow or stem no evidence of disease at the time of transplantation due to cell infusion until the ANC was у5000/l. A subset of either the achievement of CR with induction chemotherapy patients received both G-CSF and GM-CSF daily.
(seven patients) or surgical resection of all disease (five patients). Two patients had inflammatory carcinoma of Criteria for evaluation and endpoint definitions the breast.
Complete response was defined as the disappearance of all clinical evidence of active tumor except previously evident ance of any new lesion or the reappearance of the lesion IV 33 69 in a patient who was in CR or an increase of 50% or more IV (NED) 12 25 in the sum of the products of the diameters of all premeas- ously daily, and five patients received both G-CSF and were inevaluable because they had either only bone disease GM-CSF. (nine patients) or had no evidence of disease pre-transplant For the entire study cohort, the median time to an ANC (five patients). One patient was inevaluable because of у500/l was 11.5 days (range, 8 to 40 days) ( Table 3) . mixed response (PR of lung disease but increased pleural
The median time for neutrophil recovery for the patients effusion and increased number of abnormalities on bone who received autologous bone marrow and no post-transscan). Twenty-nine percent of all patients responded, and plant CSF was 15 days (range, 9 to 36 days) compared to 29% had either no response or progressed on therapy (Table  11 days (range, 8 to 40 days) for the cohort of patients who 2). Ten of the 20 evaluable patients (50%) responded. Two received autologous bone marrow and post-transplant CSF. patients (10%) achieved CR, five (25%) achieved PR and For the cohort which received only peripheral bloodthree (15%) had SD (all three had a Ͻ50% response). Four derived stem cells with post-transplant CSF, the median patients had relapsed within 1 year of the completion of time to neutrophil recovery was 10 days (range, 8 to 12 adjuvant therapy and were treated with surgical resection days). of a chest wall recurrence (one patient) or radiation to the axilla, chest wall and lung (three patients). Two patients For the entire study cohort, the median time to attain a relapsed more than 1 year from adjuvant chemotherapy and platelet count у20 000/l without transfusion (platelet underwent either local excision (one patient) or hormonal independence) was 14.5 days (range, 8 to 44 days). The therapy (one patient) and proceeded directly to transplant median time for platelet independence among patients who without cytoreductive chemotherapy. Seven patients received autologous bone marrow without CSF was 22 days presented with stage IV disease (one bone, one inflamma-(range, 13 to 40 days), compared to 14 days (range, 9 to tory breast cancer, one chest wall, one supraclavicular node, 42 days) for the cohort who received autologous marrow one liver, one liver and bone, one skin) and proceeded to and CSF and 12 days (range, 8 to 44 days) for the patients transplant following chemotherapy. Three of these seven receiving peripheral blood stem cells and post-transplant patients responded (inflammatory breast cancer, liver and CSF. Two patients failed to show platelet recovery. One bone and skin), one had no response, one was inevaluable patient, with inflammatory breast cancer, died on day 42 because she had only bone disease and two had no evidence after transplant of bleeding from profound refractory thromof disease at the time.
bocytopenia (platelet count 1000 to 5000/l), despite trilineage engraftment. The second patient had persistent severe thrombocytopenia and developed PD on day 91 after Engraftment transplant. A bone marrow was not available for further All patients are evaluable for engraftment. Thirty patients evaluation at that time. (63%) received only autologous bone marrow as the source of progenitor cells, 15 (31%) received only PBPCs and A = adriamycin; V = vinblastine; C = cyclophosphamide; M = methotrexate; CDDP = cisplatin; F and 5-FU = 5-fluorouracil; VP16 = etoposide. a One patient had a CR in the liver and improvement on a bone scan. b Five patients were inevaluable because they had only bone disease pre-transplant, and two patients had no evidence of disease pre-transplant. c One patient received CA. d One patient was inevaluable because she had only bone disease, and three patients were inevaluable because they had no evidence of disease pre-transplant. e One patient was inevaluable because of a mixed response f Two patients were inevaluable because they had only bone disease pre-transplant. Significantly different from no post-transplant CSF (P Ͻ 0.0083).
Response Treatment-related deaths occurred in two patients (4%), and both occurred early after transplant. One patient with a Forty-eight patients received high-dose chemotherapy with history of significant tobacco use and only bone metastases autologous bone marrow or peripheral stem cell transplan-(sternum) at the time of transplantation died of idiopathic tation. Twelve patients had no evidence of disease at the interstitial pneumonitis on day 42. She had received 2880 time of transplantation, and two died early; therefore, 34 cGy with electrons pre-transplant to the sternum. The patients are evaluable for response. Three of the 34 patients second patient with inflammatory breast cancer had (9%) evaluable for response to high-dose chemotherapy received neoadjuvant CAF chemotherapy. She had no eviachieved a CR, eight patients (24%) achieved a PR, 12 dence of disease at the time of transplantation and died of patients (35%) had SD (six with bone disease only) and 11 uncontrollable gastrointestinal hemorrhage due to profound patients (32%) had PD. refractory thrombocytopenia on day 42.
Post-transplant chemotherapy Post-transplant chemotherapy toxicities:
Toxicities of post-transplant chemotherapy were quite limited among the Thirty-three patients (69%) received at least one cycle of 33 patients receiving at least one cycle. The predominant post-transplant chemotherapy. Fifteen patients (31%) were toxicity of post-transplant chemotherapy was myelosupable to receive all four planned cycles. Fifteen patients pression seen in 10 patients (33%), which resulted in a dose (31%) did not receive post-transplant chemotherapy reduction during at least one cycle. Nausea and/or emesis because of either early death (two patients) or PD (13 occurred in seven patients (21%), mucositis in two patients patients). Between 70 and 80% of patients were adminis-(6%) and abdominal pain in one patient (3%). One patient tered 100% doses in each cycle.
developed transient acute renal failure manifested by elevation in the creatinine after the first cycle, and one patient Toxicity developed a left subclavian vein thrombosis.
Acute toxicity during high-dose chemotherapy:
The highdose chemotherapy was generally well-tolerated. The most Patterns of relapse and progression common nonhematologic grade III or IV toxicities were Among the 35 patients receiving pre-transplant cytoreduchepatotoxicity in seven patients (15%), skin rash in five tive chemotherapy responding to high-dose chemotherapy patients (10%), diarrhea and infection in six patients (13%) (CR or PR) or demonstrating SD or without evidence of each, fever without infection in four patients (8%), nausea disease at transplant, relapse or progression subsequently and vomiting and stomatitis and/or esophagitis (one culoccurred in 24 patients (69%). Sites of relapse or proture-positive for herpes virus) in three patients (6%) each.
gression included sites of prior disease in 15 patients and The seven cases of hepatotoxicity reflect transient elevnew sites of disease in eight patients (one bone marrow, ations in transaminases and total serum bilirubin. The cases three liver, two brain, one chest wall, and one eyelid and of skin rash were presumably drug related and all resolved. labia). Three of these eight patients had received all four Of the six patients who developed a grade III or IV infeccycles of post-transplant chemotherapy, two received two tion, there were four cases of bacteremia, including Pseudocycles, one received one cycle and two had not received monas maltophilia, Enterobacter species, Staphylococcus any. Four of the eight had received marrow-derived stem haemolyticus and Enterococcus faecalis, one case of cytocells, three received blood-derived stem cells and one megalovirus infection and one case of Staphylococcus haereceived both. One patient, who was known to have molyticus endocarditis. The two neurologic events were relapsed, relocated and was lost to follow-up. very transient episodes of loss of consciousness believed to represent vasovagal episodes from which both patients recovered without consequences. All patients developed Event-free survival pancytopenia with neutropenic fevers requiring broad-spectrum antibiotics. No patient died of bacterial sepsis. Thirty-
The median follow-up is 24.5 months (range, 1 to 96 months). The actuarial probability of EFS is 17% (95% CI, nine patients received intravenous hyperalimentation. cycles of post-transplant chemotherapy was 27% (95% CI, 7-60%) at 4 years ( Figure 1) . The EFS for patients receivchemotherapy is 40% (95% CI, 11-74%), compared to 20% ing any post-transplant chemotherapy is 17% at 4 years for patients not receiving post-transplant chemotherapy (95% CI, 4-49%). The EFS for patients not receiving any ( Figure 3 ). No patients receiving at least one cycle of postpost-transplant chemotherapy is 36% at 1 year. There was transplant chemotherapy, but less than four cycles, survived only one patient surviving event-free at 2 years or longer. beyond 4 years. The OS for patients without evidence of The EFS for patients without evidence of disease at transdisease at transplant is 50% at 4 years and 40% for patients plant is 44% at 4 years and 20% at 4 years for patients with only bone disease, compared to 8% for patients with with only bone disease, compared to 8% at 2 years and 4% visceral or soft tissue disease (Figure 4) . The OS for the at 4 years for patients with visceral or soft tissue disease nine patients receiving the higher dose of cyclophospham- (Figure 2) . ide was better (44% at 4 years) than that for the 38 patients receiving the lower dose (21%), although there was no Overall survival statistical difference (P = 0.2). Ten of the 48 patients (21%) are alive, and seven (15%) have no evidence of disease at 4 years. Of the seven Discussion patients who are alive and free of disease, five had no evidence of disease at the time of transplantation, and two had
In the present study, seven of 48 patients (15%) with metaonly bone disease, with multiple lesions, at transplantation. static breast cancer remain alive and event-free at 4 years Thirty-one patients (excluding two treatment-related following high-dose chemotherapy and autologous bone deaths) died of recurrent or progressive breast cancer. The marrow or stem cell transplantation. Patients without eviactuarial survival is 25% (95% CI, 0-42%) at 4 years. The OS for patients receiving all four cycles of post-transplant Months Percent survival
Log-rank test P = 0.002 Figure 2 Event-free survival for all patients according to whether Figure 4 Overall survival for all patients according to whether (---) or not (---) they were free of disease at the time of transplant or (---) or not (---) they were free of disease at the time of transplant or whether they had only bone disease (---).
whether they had only bone disease (---).
dence of disease at the time of transplant fared well, with plant chemotherapy were prevented from doing so because of PD. Finally, since this was not a prospective randomized an EFS of 44% at 4 years. Toxicity was acceptable, and there were only two (4%) treatment-related deaths. No trial, we cannot exclude the possibility that these patients would have fared equally well without such therapy. A ranpatient reported here was excluded from treatment because of extent of disease or pre-transplant chemotherapy domized trial with an intention-to-treat analysis would be required to establish whether or not post-transplant consoliresistance.
This trial represents a large series of patients with metadation chemotherapy has an important beneficial impact independent of performance status, extent of disease, sites static breast cancer with relatively long follow-up, which is important, since early outcome analyses of a novel of disease and other potentially important prognostic factors. Recently, 21 patients with previously untreated metaapproach may be misleading. The observation that a small, but definite, proportion of patients may enjoy prolonged static breast cancer were given high-dose chemotherapy and three cycles of post-transplant doxorubicin with EFS suggests that the natural history of breast cancer in this subset of patients may be altered. However, even acceptable toxicity. 27 Since tumor cells may contaminate marrow harvests and longer follow-up will be required to determine if such patients are actually cured. These results compare favorably contribute to relapse, several alternative strategies to reduce the relapse rate have been suggested. Such strategies with other studies carried out in a similar patient population. In the aggregate experience, 10 to 20% of patients included the development of techniques for eliminating malignant clonogenic tumor cells from the bone marrow, [28] [29] [30] [31] in other reports remain disease-free for prolonged periods of time and may be cured. [5] [6] [7] [8] [9] [10] [11] [12] [13] A large percentage of patients the collection of hematopoietic stem cells from the peripheral blood with fewer clonogenic tumor cells compared to entered on the trial reported here had poor prognostic factors, including younger age, ER-negative disease, presence stem cells harvested from the bone marrow, 32 and the reinfusion of CD34 + -enriched progenitor cells, 33, 34 which of visceral disease and prior therapy for metastases. However, this selection bias is not unique to the present study reduces the number of malignant cells, thereby successfully purging the autograft of breast cancer cells. Randomized and is problematic in many transplant trials for patients with metastatic or poor prognosis breast cancer, who are clinical trials will be required to determine whether the use of peripheral blood-derived stem cells or purging will have often selectively referred for novel and aggressive approaches.
any meaningful benefit for patients. Five of the seven patients (71%) remaining disease-free Few studies have addressed the factors which predict for a favorable outcome after high-dose chemotherapy. Ayash had no evidence of active disease at the time of transplantation, and two (29%) had only bone disease. This suggests and colleagues 10 identified a single metastatic site and achievement of CR with induction chemotherapy in a that patients with minimal disease at the time of transplantation fare significantly better than patients with large tumor multivariate analysis. In the latter series, the 5-year PFS is 21%, which is consistent with the results reported here. For burdens, an observation that is consistent with a recently published report. 10 The EFS of 44% at 4 years for patients patients achieving CR with pre-transplant chemotherapy, the 5-year PFS is 31%.
in CR at the time of transplant is encouraging. This is consistent with results of Peters and colleagues, 35 who report To reduce the rate of recurrence, we explored the benefits of post-transplant consolidation chemotherapy administered a shorter disease-free interval for patients in CR following induction chemotherapy compared to those immediately to eradicate the small numbers of malignant cells theoretically reinfused with the autograft, which potentially may transplanted in CR. Furthermore, the observations reported here suggest that treating patients even earlier in the natural lead to systemic relapse. We and others have previously shown that tumor cells in the marrow may be present more history of the disease will result in more patients remaining disease-free for longer periods of time. Indeed, Peters and often than is apparent from morphology alone.
14-18 5-Fluorouracil and cisplatin were selected because of their activity colleagues 36 reported that the actuarial EFS for breast cancer in 85 women with stage IIA, IIB, IIIA, and IVB breast and relative lack of myelosuppression. The EFS and OS among patients receiving four cycles of post-transplant cancer involving 10 or more axillary lymph nodes receiving high-dose chemotherapy was 79% at 2.5 years. chemotherapy was better than that for patients not receiving such treatment or patients receiving fewer than all four
The first randomized trial comparing high-dose to conventional-dose chemotherapy as initial treatment for metacycles. The full benefit of post-transplant therapy may not have been demonstrated because, although 33 of the 48 static breast cancer has shown a higher response rate, longer remission duration and OS for the high-dose treatpatients (69%) received post-transplant 5-FU and cisplatin, only 15 of the 33 patients (45%) were able to receive all ment. 37 However, the median response duration and survival for the patients receiving conventional-dose chemofour scheduled courses. Furthermore, three of these 15 patients required a dose reduction because of chemotherapy was quite short (median, 34 and 45 weeks, respectively); and even on the high-dose arm, less than 20% therapy-induced cytopenias. The observation that patients receiving four cycles of post-transplant chemotherapy had of patients are alive at 3 years. A large, prospective, randomized trial comparing maintenance chemotherapy to improved EFS and OS should be cautiously interpreted. Those patients able to receive the most post-transplant high-dose chemotherapy with autologous marrow support for patients with metastatic breast cancer is underway. 
